fludarabine and snx-7081

fludarabine has been researched along with snx-7081 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Best, OG; Che, Y; Christopherson, RI; Forsyth, C; Mulligan, SP; Singh, N	1
Alomari, M; Best, OG; Christopherson, RI; Haynes, PA; Jenkins, Y; Kaufman, KL; Mactier, S; Mirzaei, M; Mulligan, SP; Pascovici, D	1

Other Studies

2 other study(ies) available for fludarabine and snx-7081

Article	Year
The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia & lymphoma, 2012, Volume: 53, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzamides; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Protein Serine-Threonine Kinases; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine	2012
The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Oncotarget, 2015, Dec-01, Volume: 6, Issue:38 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; BRCA1 Protein; Cell Line, Tumor; Chromatography, Liquid; Cyclin D1; DNA Damage; DNA Repair; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; NF-kappa B p52 Subunit; Nucleolin; Phosphoproteins; Protein Interaction Maps; Proteomics; Proto-Oncogene Proteins c-myc; RNA-Binding Proteins; Signal Transduction; Tandem Mass Spectrometry; Tumor Suppressor Protein p53; Vidarabine	2015

Article

Year

The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.

Leukemia & lymphoma, 2012, Volume: 53, Issue:7

Topics: Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzamides; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Protein Serine-Threonine Kinases; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

2012

The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.

Oncotarget, 2015, Dec-01, Volume: 6, Issue:38

Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; BRCA1 Protein; Cell Line, Tumor; Chromatography, Liquid; Cyclin D1; DNA Damage; DNA Repair; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; NF-kappa B p52 Subunit; Nucleolin; Phosphoproteins; Protein Interaction Maps; Proteomics; Proto-Oncogene Proteins c-myc; RNA-Binding Proteins; Signal Transduction; Tandem Mass Spectrometry; Tumor Suppressor Protein p53; Vidarabine

2015